Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MicroRNA or Its Inhibitors in the Regulation of Lipid Metabolism

An inhibitor, lipid metabolism technology, applied in DNA/RNA fragments, metabolic diseases, recombinant DNA technology, etc., can solve problems such as the decline in the ability of macrophages to uptake lipoproteins

Active Publication Date: 2016-03-30
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that PPAR-γ may inhibit the expression of scavenger receptor SR-A (scavenger receptor A) by inhibiting the activity of transcription factor activation protein-1 (AP-1), leading to a decrease in the ability of macrophages to uptake lipoproteins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MicroRNA or Its Inhibitors in the Regulation of Lipid Metabolism
  • Application of MicroRNA or Its Inhibitors in the Regulation of Lipid Metabolism
  • Application of MicroRNA or Its Inhibitors in the Regulation of Lipid Metabolism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0113] Example 1, miR-96, miR-185 and miR-223 regulate important targets of cholesterol reverse transport SR-BI.

[0114] 1.1. Effect of Dicer and Drosha gene silencing on SR-BI mRNA level

[0115] After knocking out two key enzymes Dicer and Drosha in the process of microRNA biosynthesis by siRNA gene silencing technology, the Real-timeRT-PCR method was used to detect the level of SR-BI mRNA.

[0116] The experimental results showed that after Dicer or Drosha gene silencing, the level of SR-BI mRNA was significantly up-regulated, indicating that microRNA is involved in the regulation of SR-BI (such as figure 1 shown).

[0117] 1.2. Regulatory effects of miR-96, miR-185, miR-223 and their antagonists on SR-BI mRNA and protein expression levels.

[0118] The miRNA antagonist (anti-miR) of the present invention is purchased from QIAGEN, and its sequence and article number are respectively:

[0119] anti-miR-96 (Cat.no.MIN0000095)

[0120] 5'-agcaaaaaugugcuagugccaaa-3' (SEQ...

Embodiment 2

[0140] Example 2, the regulation of miR-96 and miR-223 on ABCA1, an important target of cholesterol reverse transport Festival.

[0141] 2.1. Target prediction and homology analysis of miR-96, miR-223 and ABCA13'UTR.

[0142] MicroRNA.org and TargetScan predicted the interaction sites of miR-96 and miR-223 with ABCA13'UTR. ClustalX2 software was used to compare the predicted target sequences of miR-96 and miR-223 of ABCA13'UTR in multiple species.

[0143] Forecast results such as Figure 8 As shown, there is one predicted target of miR-96 and one of miR-223 on ABCA13'UTR. The sequence alignment results are as Figure 9 As shown, the predicted targets of miR-96 and miR-223 present on ABCA13'UTR showed sequence conservation in multiple species (Hsa human; Ptr chimpanzee; Pab Sumatran chimpanzee; Ame giant panda; Mmu mouse).

[0144] 2.2 Regulatory effects of miR-96, miR-223 and their antagonists on ABCA1 mRNA levels

[0145] LipofectamineRNAiMAX Transfection Reagent tr...

Embodiment 3

[0147] Example 3, regulation of LDLR by miR-185 and its antagonists.

[0148] 3.1. Prediction and homology analysis of direct action targets of miR-185 and LDLR3'UTR.

[0149] MicroRNA.org and TargetScan predicted the interaction sites of miR-185 and LDLR3'UTR. The ClustalX2 software was used to compare the miR-185 predicted target sequences of LDLR3'UTR in multiple species.

[0150] Forecast results such as Figure 11 As shown, there are two predicted targets of miR-185 on LDLR3'UTR. The sequence alignment results are as Figure 12 As shown, the predicted target of miR-185 present on LDLR3'UTR exhibits sequence conservation in multiple species (Hsa human; Ptr chimpanzee; Pab Sumatran chimpanzee; Bta cattle).

[0151] 3.2. Regulation of LDLR mRNA levels by miR-185 and its antagonists

[0152] LipofectamineRNAiMAX Transfection Reagent transiently transfected miR-185 or its antisense oligonucleotide inhibitor into liver cancer cell HepG2 cells, and after 72 hours of actio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of microRNA or its inhibitor, in particular to the use of microRNA or its inhibitor in the preparation of medicines for regulating lipid metabolism or the preparation of medicines for preventing or treating diseases related to lipid metabolism. The microRNAs include miRNA-96, miRNA- One or more of 185 and miRNA-223. The present invention also relates to the use of the microRNA or its inhibitor for regulating the expression level of lipid metabolism-related proteins. The present invention also relates to compositions comprising said microRNA or an inhibitor thereof. The microRNA or its inhibitor described in the present invention can be used as a pharmaceutical component to prevent or treat hyperlipidemia, atherosclerosis, coronary heart disease and other related diseases caused by lipid metabolism disorder.

Description

technical field [0001] The present invention relates to the use of microRNA or its inhibitor, in particular to the use of microRNA or its inhibitor in the preparation of medicines for regulating lipid metabolism or the preparation of medicines for preventing or treating diseases related to lipid metabolism. In addition, microRNA or its inhibitors can be used as a tool drug for the above-mentioned related diseases or the functional mechanism research of related proteins. The present invention also relates to the use of the microRNA or its inhibitor for regulating the expression level of lipid metabolism-related proteins. The present invention also relates to compositions comprising said microRNA or its antisense oligonucleotide inhibitor. Background technique [0002] Atherosclerotic cardiovascular and cerebrovascular diseases are the most disabling and fatal diseases worldwide, and dyslipidemia is one of the most important risk factors for atherosclerosis. It has been a lo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K48/00A61P3/00A61P3/06A61P9/10A61P9/00A61P25/28A61P3/04A61P3/10C12Q1/68
CPCA61K31/7105A61K31/713A61P3/00A61P3/04A61P3/06A61P3/10A61P9/00A61P9/10A61P25/28C12N15/113C12N2310/113C12N2310/141C12Q1/6883C12Q2600/136C12Q2600/158C12Q2600/178G01N2405/00G01N2500/04G01N2800/044C12N2320/30C12Q1/6897G01N33/92G01N2500/10
Inventor 洪斌王丽贾晓健姜华军杜郁杨帆司书毅
Owner MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com